Endoscopy 2019; 51(04): S258
DOI: 10.1055/s-0039-1681949
ESGE Days 2019 ePosters
Friday, April 5, 2019 09:00 – 17:00: Stomach and small intestine ePosters
Georg Thieme Verlag KG Stuttgart · New York

THE MANAGEMENT OF GASTRIC MALT LYMPHOMA

SH Lee
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
MC Kim
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
MK Kang
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
JH Cho
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
SB Kim
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
KH Kim
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
KO Kim
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
BI Jang
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
,
TN Kim
1   Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2019 (online)

Also available at
 

Aims:

Helocibacter pylori (H.pylori) eradication is an effective treatment in H.pylori-positive mucosa-associated lymphoid tissue (MALT) lymphoma. However, the complete remission (CR) rates after H.pylori eradication in H.pylori-negative MALT lymphoma is very low and the treatment strategy remains controversial. We investigated the effectiveness of each treatment option for H.pylori-negative MALT lymphoma and H.pylori-positive MALT lymphoma with treatment failure after H.pylori eradication.

Methods:

We conducted retrospective single center study using medical records of patients who were diagnosed with gastric MALT lymphoma in Yeungnam University Medical Center between January 2005 and December 2016. Response to each treatment options and relapse after CR were evaluated by pathologic base using endoscopic biopsy.

Results:

Of the 68 patients, 50 patients were enrolled. Mean ages were 55.4 ± 11.7 years and mean follow-up periods were 42.5 ± 31.0 months (range: 3 – 133.6). H.pylori infection was detected in 42 patients (84.0%). Of these H.pylori-positive MALT lymphoma, 36 patients (81.7%) were treated with H.pylori eradication as primary treatment and the CR rates after H.pylori eradication was 72.2% (n = 26). Patients without CR after H.pylori eradication (n = 10, 27.8%) were received radiotherapy as secondary treatment. All of them were shown CR and no one had relapse after radiotherapy. 2 patients (4.8%) of H.pylori-positive MALT lymphoma were treated with radiotherapy as primary manner and all reached CR. 1 of them (50%) had relapse after treatment, but another CR had been achieved after 2ndary radiotherapy. All patients with H.pylori-negative MALT lymphoma (n = 8, 16.0%) were treated with radiotherapy as primary treatment. The CR rates after radiotherapy was 100% and no one had had relapse after radiotherapy.

Conclusions:

Although H.pylori eradication is effective treatment in H.pylori-positive MALT lymphoma, radiotherapy may be worthwhile treatment option in H.pylori-negative MALT lymphoma and H.pylori-positive MALT lymphoma as 2ndary treatment after H.pylori eradication.